Related Experiment Video
Updated: Apr 18, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis
Yuanjie Hu1, Hengjun Gao2, Christopher Vo3
1Department of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Abstract:
EGFR is one of the key oncogenes subjected to targeted therapy for several cancers, as it is known to be amplified and/or mutated in up to 40% of malignant gliomas. EFEMP1, a fibulin-like extracellular protein, exerts both tumor suppressive and oncogenic effects in various cancers and glioma cell models. Although EFEMP1's anti-cancer activity has most commonly been attributed to its anti-angiogenic effects, we showed for gliomas that EFEMP1's binding to EGFR accounts for its suppression of the intracranial tumorigenicity of glioma cells expressing high levels of EGFR. In gliomas where EFEMP1 expression, and thus the anti-EGFR effect of EFEMP1, was suppressed, heightened levels of EGFR expression were associated with unfavorable patient outcomes in prognostic models. Results from the current study clearly demonstrate the impact that the anti-EGFR function of EFEMP1 has on the expression of EGFR and patient prognosis. A glioma prognostic model also suggests EFEMP1's context-dependent oncogenic function in gliomas expressing low levels of EGFR. Hence the level of EFEMP1 expression may have a predictive value for choosing patients for anti-EGFR therapy.
Insights
EFEMP1 binds to EGFR, suppressing glioma growth. EFEMP1 levels predict patient prognosis and may guide anti-EGFR therapy selection in gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) is a key oncogene in various cancers, including malignant gliomas.
- EFEMP1, a fibulin-like protein, has demonstrated both tumor-suppressive and oncogenic roles in cancer.
- EFEMP1's anti-cancer effects are often linked to anti-angiogenesis, but its direct interaction with EGFR in gliomas is less understood.
Purpose of the Study:
- To investigate the role of EFEMP1's interaction with EGFR in suppressing glioma tumorigenicity.
- To determine the impact of EFEMP1 expression on EGFR levels and patient prognosis in gliomas.
- To explore the potential of EFEMP1 as a predictive biomarker for anti-EGFR therapy.
Main Methods:
- Analysis of EFEMP1-EGFR binding in glioma cell models.
- Correlation of EFEMP1 expression with EGFR levels and patient outcomes using prognostic models.
- Investigation of EFEMP1's functional impact on glioma cell tumorigenicity in vivo.
Main Results:
- EFEMP1 binding to EGFR suppresses intracranial glioma cell tumorigenicity in EGFR-high gliomas.
- Reduced EFEMP1 expression correlates with increased EGFR levels and poorer patient prognosis.
- A glioma prognostic model indicates EFEMP1's context-dependent oncogenic function in low-EGFR gliomas.
Conclusions:
- EFEMP1's anti-EGFR activity significantly influences EGFR expression and patient prognosis in gliomas.
- EFEMP1 expression levels may serve as a predictive biomarker for selecting glioma patients for anti-EGFR targeted therapy.
- EFEMP1 exhibits context-dependent functions in gliomas, highlighting its complex role in tumorigenesis.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:21Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal